Hemodynamic effects of finerenone on blood pressure and heart rate in hospitalized patients with type 2 diabetes: a real-world study - Report - MDSpire
Advertisement
Hemodynamic effects of finerenone on blood pressure and heart rate in hospitalized patients with type 2 diabetes: a real-world study
Clinical Report: Acute Hemodynamic Impact of Finerenone on Blood Pressure
Overview
This study evaluates the acute effects of finerenone on blood pressure and heart rate in hospitalized patients with type 2 diabetes. Results indicate reductions in blood pressure within the first 24-48 hours of treatment, while heart rate remained stable.
Background
Type 2 diabetes mellitus is a major global health concern, with diabetic kidney disease being a severe complication. Current treatments often do not fully address the underlying mechanisms of cardiorenal damage, highlighting the need for effective therapies like finerenone, which targets mineralocorticoid receptor overactivation.
Data Highlights
Parameter
Change
P-value
Systolic Blood Pressure
Decreased
< 0.0001
Diastolic Blood Pressure
Decreased
< 0.0001
Heart Rate
Stable
N/A
Key Findings
Finerenone was prescribed to patients with high urinary albumin-to-creatinine ratio (UACR).
Significant reductions in systolic and diastolic blood pressure were observed within 24-48 hours of treatment initiation.
Heart rate remained stable during the initial days of therapy.
The distribution of background antihypertensive medications did not change during finerenone treatment.
Finerenone's antihypertensive effects were noted despite concurrent use of ARBs, CCBs, and SGLT-2 inhibitors.
Clinical Implications
The findings indicate that finerenone may provide antihypertensive effects in hospitalized patients with type 2 diabetes and albuminuria.
Conclusion
Finerenone demonstrates acute antihypertensive effects in hospitalized patients with type 2 diabetes.
